Impact of Specific Monitoring of Intraoperative Analgesia Under General Anesthesia on Chronic Pain After Ovarian Cancer Surgery

Ovarian Neoplasm Clinical Trial

— MONIALC  

Official title:

Impact of Specific Monitoring of Intraoperative Analgesia Under General Anesthesia on Chronic Pain After Ovarian Cancer Surgery. The MONIALC Study.

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04906187
• Other study ID #: IB 2020-04
• Secondary ID: 2020-A02767-32
• Status: Recruiting
• Phase: N/A
• Start date: May 31, 2021
• Est. completion date: August 25, 2024

Study information

• Verified date: February 2023
• Source: Institut Bergonié
• Contact: Arnaud DUBUISSON, Nurse
• Phone: (0)5.56.33.37.30
• Email: a.dubuisson[@]bordeaux.unicancer.fr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a single-center, randomized, phase II, non-comparative, single-blind clinical study that will determine whether morphine reduction through intraoperative monitoring by ANI (Analgesia Nociception Index) significantly reduces chronic post-surgical pain at three months after laparotomy for ovarian carcinoma with regard to standard care.

Description:

Prior to carrying out the research, the informed consent of the person must be obtained after being informed of the purpose of the research, its conduct and duration, benefits, potential risks and constraints of the study. Before inclusion,all eligibility criteria will be verified, VAS pain score and VAS anxiety will be performed. The surgical procedure for ovarian carcinoma will be performed by laparotomy and the intraoperative monitoring of nociception wil depend of the randomization arm : Intraoperative ANI monitoring of nociception (experimental arm) versus no specific monitoring of nociception (control arm). The total dose of opioids (in micrograms) received by the patients will be recorded at the end of the surgery. VAS pain score will be performed immediately postoperatively and at three months after the intervention. A DN4 questionnaire (neuropathic pain) will be evaluated at three months after the intervention.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 126
• Est. completion date: August 25, 2024
• Est. primary completion date: February 25, 2024
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Woman aged 18 years and over.

2. Histologically proven or strongly suspected ovarian carcinoma.

3. Indication for laparotomy surgery with xyphopubic incision.

4. Acceptance of epidural anesthesia.

5. Pain score = 3 (VAS or Numeric Verbal Scale).

6. Free and informed consent.

7. Patient affiliated with a French social security scheme in accordance with French law on research involving human participants.

Exclusion Criteria:

1. Heart rhythm disturbances.

2. History of Cerebral Vascular Accident (CVA).

3. History of epilepsy.

4. Wearing a pacemaker.

5. Receiving morphine treatment preoperatively.

6. Medical contraindication to an epidural.

7. Patient unable to follow and adhere to trial procedures for geographic, social or psychological reasons.

8. Patient placed under guardianship or curatorship.

9. Patient already included in the present study.

Related Conditions & MeSH terms

• Chronic Pain
• Ovarian Neoplasm
• Ovarian Neoplasms

Intervention

Other:
• Arm A : intraoperative ANI monitoring of nociception
For the experimental group (arm A), the sufentanil doses are adjusted to maintain an ANI between 50 and 70. Morphine doses are adjusted from 0.05 to 0.05 µg / ml. Intraoperative data will be collected for ANI, TIVA and hemodynamics.
• Arm B : no specific monitoring of nociception
For the control group (arm B), adjustments to the opioid doses are made in relation to the hemodynamic reactions of the patient and the operating times. Intraoperative data will be collected for TIVA and hemodynamics.

Locations

Country	Name	City	State
France	Institut Bergonié	Bordeaux

Sponsors (1)

Lead Sponsor	Collaborator
Institut Bergonié

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Proportion of patients with a pain score on the self-assessment VAS > 4, three months after the surgery.	The Visual Analog Scale (VAS) is a validated, reliable and reproducible tool. The VAS will be used to measure pain. This self-assessment scale allows the patient to evaluate his or her pain from 0 to 10 "0=No pain" to "10=Maximum imaginable pain ". A pain VAS score of 4 and above is considered clinically significant.	3 months after surgery
Secondary	Arm A : total dose of opioids received intraoperatively		Surgery
Secondary	Arm B : total dose of opioids received intraoperatively		Surgery
Secondary	Arm A : Patients' pain score on the VAS immediately postoperatively	The Visual Analog Scale (VAS) is a validated, reliable and reproducible tool. The VAS will be used to measure pain. This self-assessment scale allows the patient to evaluate his or her pain from 0 to 10 "0=No pain" to "10=Maximum imaginable pain ". A pain VAS score of 4 and above is considered clinically significant.	within one hour of extubation
Secondary	Arm B : Patients' pain score on the VAS immediately postoperatively	The Visual Analog Scale (VAS) is a validated, reliable and reproducible tool. The VAS will be used to measure pain. This self-assessment scale allows the patient to evaluate his or her pain from 0 to 10 "0=No pain" to "10=Maximum imaginable pain ". A pain VAS score of 4 and above is considered clinically significant.	within one hour of extubation
Secondary	Arm A : proportion of patients with a DN4 questionnaire score> 4, three months after surgery		3 months after surgery
Secondary	Arm B : Arm A : proportion of patients with a DN4 questionnaire score> 4, three months after surgery		3 months after surgery